Take a look at the latest on Palatin across our media publications, posters, and presentations.
Therapeutically targeting the melanocortin pathway represents a novel approach to the treatment of ocular diseases. Synthetic MCr receptor agonists show promise in the treatment of uveitis and retinopathy in preclinical animal models and PL9643 has demonstrated efficacy in treating signs and symptoms of dry eye disease in humans.
Protective Effects of Two Melanocortin Agonists Delivered by Intravitreal Injection in Mouse Models of Retinopathy
Melanocortin agonists have demonstrated anti-inflammatory effects in various experimental models of inflammatory disease. PL8331 and PL9654 are melanocortin 1 receptor agonists being evaluated preclinically for the treatment of various ocular diseases.
Melanocortin Agonists for Ocular Diseases
Protective Effects of 2 Melanocortin Agonists Delivered by Intravitreal Injection in Mouse Models of Retinopathy
Melanocortins have a wide range of activities, including inhibition of leukocyte activation, inhibition of inflammation, and protection of tissues1-3 The melanocortin system plays a key role in promoting resolution of the inflammatory process
Efficacy and Safety of the Melanocortin Agonist PL9643 in a Phase 2 Study of Subjects With Dry Eye Disease
This is a multifactorial inflammatory disease affecting multiple areas in the eye. Existing therapies are often inadequate due to poor efficacy, adverse effects, or poor tolerability.